Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade

Cancer Immunology Research

Volumn 3, Issue 11, 2015, Pages 1269-1278

  Kelleher, Raymond ^a   Balu Iyer, Sathy ^b   Loyall, Jenni ^a   Sacca, Anthony J ^a   Shenoy, Gautam N ^a   Peng, Peng ^a   Iyer, Vandana ^b   Fathallah, Anas M ^b   Berenson, Charles S ^a   Wallace, Paul K ^c,d   Tario, Joseph ^c,d   Odunsi, Kunle ^d   Bankert, Richard B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VA Western New York Health Care System   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLSERINE; LIPID;

ARTICLE; ASCITES TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; EXOSOME; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MOLECULAR PATHOLOGY; OVARY TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ASCITES; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ASCITES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EXTRACELLULAR VESICLES; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; LIPIDS; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; PHOSPHATIDYLSERINES; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 84948181477     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0086     Document Type: Article

References (50)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
2. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N Engl J Med 2013;368:1509-18.
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33.
7. Steinman RM, Mellman I Immunotherapy: Bewitched, bothered, and bewildered no more. Science 2004;305:197-200.
8. Broderick L, Brooks SP, Takita H, Baer AN, Bernstein JM, Bankert RB. IL-12 reverses anergy to T cell receptor triggering inhuman lung tumor-associated memory T cells. Clin Immunol 2006;118:159-69.
9. Koneru M, Schaer D, Monu N, Ayala A, Frey AB. Defective proximal TCR signaling inhibits CD8 tumor-infiltrating lymphocyte lytic function. J Immunol 2005;174:1830-40.
10. Monu N, Frey AB. Suppression of proximal T cell receptor signaling and lytic function in CD8 tumor-infiltrating T cells. Cancer Res 2007; 67:11447-54.
11. Simpson-AbelsonM, Bankert RB. Targeting the TCR signaling checkpoint: A therapeutic strategy to reactivate memory T cells in the tumor microenvironment. Expert Opin Ther Targets 2008;12:477-90.
12. Vazquez-Cintron EJ, Monu NR, Frey A. B. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8 lymphocytes inactivates antitumor effector phase. J Immunol 2010; 185:7133-40.
13. Yokota SJ, Facciponte JG, Kelleher RJ Jr, Shultz LD, Loyall JL, Parsons RR, et al. Changes in ovarian tumor cell number, tumor vasculature, and T cell functionmonitored in vivo using a novel xenograft model. Cancer Immun 2013;13:11.11-11.
14. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014;20:4262-73.
15. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
16. Quezada SA, Peggs KS, Simpson TR, Allison J. P. Shifting the equilibrium in cancerimmunoediting: From tumor tolerance to eradication. Immunol Rev 2011;241:104-18.
17. Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, et al. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kB and NFAT signaling in tumor-associated T cells. Cancer Immun 2013;13: 14.11-10.
18. Thery C, Amigorena S, RaposoG, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006;Chapter 3:30:33.22:33.22.31-33.22.29.
19. Mourdjeva M, Kyurkchiev D, Mandinova A, Altankova I, Kehayov I, Kyurkchiev S. Dynamics ofmembrane translocation of phosphatidylserine during apoptosis detected by a monoclonal antibody. Apoptosis 2005;10:209-17.
20. Gaitonde P, Ramakrishnan R, Chin J, Kelleher RJ Jr, Bankert RB, Balu-Iyer SV. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. J Biol Chem 2013;288:17051-6.
21. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-8.
22. Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 2005;174:1393-404.
23. Zhong XP, Hainey EA, Olenchock BA, Jordan MS, Maltzman JS, Nichols KE, et al. Enhanced T cell responses due to diacylglycerol kinase zeta deficiency. Nat Immunol 2003;4:882-90.
24. Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, et al. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 2006;7:1174-81.
25. Taylor DD, Doellgast GJ. Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal Biochem 1979;98:53-59.
26. Mazzaferro PK, Repasky EA, Black J, Kubo RT, Bankert R. B. Biochemical and ultrastructural characterization of a novel cell structure associatedwith immunoglobulin secretion in B-lymphocytes. J Mol Cell Immunol 1987; 3:293-306.
27. Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 2014;3:26913.
28. Keller S, Konig AK, Marme F, Runz S, Wolterink S, Koensgen D, et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 2009;278:73-81.
29. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014;14:195-208.
30. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005;92:305-11.
31. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: Mediators of cancerassociated immunosuppressive microenvironments. Semin Immunopathol 2011;33:441-54.
32. Tickner JA, Urquhart AJ, Stephenson SA, Richard DJ, O'Byrne KJ. Functions and Therapeutic Roles of Exosomes in Cancer. Front Oncol 2014;4: 127.121-128.
33. Whiteside T. L. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013;41:245-51.
34. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol 2002;168:3235-41.
35. Perone MJ, Larregina AT, Shufesky WJ, Papworth GD, Sullivan ML, Zahorchak AF, et al. Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells. J Immunol 2006;176:7207-20.
36. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005;11:1010-20.
37. Wherry EJ. T cell exhaustion. Nature immunology 2011;12:492-99.
38. Mueller DL. Linking diacylglycerol kinase to T cell anergy. Nat Immunol 2006;7:1132-4.
39. Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinasealpha. Nat Immunol 2006;7:1166-73.
40. Abe T, Lu X, Jiang Y, Boccone CE, Qian S, Vattem KM, et al. Site-directed mutagenesis of the active site of diacylglycerol kinase alpha: Calcium and phosphatidylserine stimulate enzyme activity via distinct mechanisms. Biochem J 2003;375:673-80.
41. Kranich J, Krautler NJ, Heinen E, Polymenidou M, Bridel C, Schildknecht A, et al. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med 2008;205:1293-302.
42. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: Another mechanism how antigenic tumors escape immune-mediated killing. Mol Med 2000;6:465-79.
43. Broderick L, Bankert RB. Memory T cells in human tumor and chronic inflammatory microenvironments: Sleeping beauties re-awakened by a cytokine kiss. Immunol Invest 2006;35:419-36.
44. Xie Y, Zhang X, Zhao T, Li W, Xiang J. Natural CD825 regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocytemediated immunity against B16 melanoma. Biochem Biophys Res Commun 2013;438:152-55.
45. Webb Y, Hermida-Matsumoto L, Resh MD. Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem 2000;275:261-70.
46. Zeyda M, Staffler G, Horejsi V, Waldhausl W, Stulnig TM. LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. J Biol Chem 2002; 277:28418-23.
47. Shaikh SR, EdidinM. Polyunsaturated fatty acids,membrane organization, T cells, and antigen presentation. Am J Clin Nutr 2006;84:1277-89.
48. Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, et al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol 2009;183:5050-8.
49. Thornton MV, Kudo D, Rayman P, Horton C, Molto L, Cathcart MK, et al. Degradation ofNF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004;172:3480-90.
50. Crespo FA, Sun X, Cripps JG, Fernandez-Botran R. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J Leukoc Biol 2006;79:586-95.